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Chapter 1
Introduction

1.1 Prostate Cancer
Prostate carcinoma is the most frequently occurring non-cutaneous cancer and the
second leading cause of cancer related deaths in men. Over 192,000 men are diagnosed
with prostate cancer every year, and approximately 27,000 men die from the disease each
year (68). The majority of patients that die from prostate cancer exhibit bone metastases.
Prostate cancer has a high cure rate in its early stages, through the use of surgery,
radiation or hormone therapy. However, not all primary tumors are able to be eradicated
at an early stage, and to date, no effective therapy has been developed for metastatic
prostate cancer; once the primary prostate tumor has metastasized to the bone, the disease
is considered incurable. Therefore, the development of novel therapies for the treatment
of both primary and metastatic prostate cancer are critical to reduce the mortality of the
disease.
1.2 Platelet Derived Growth Factors
Platelet derived growth factors (PDGFs) are a family of four ligands, A, B, C, and
D. First identified in the mid 1970s, PDGF was found to be an important mitogen in
serum, and was first purified from platelets (75, 139, 181). Further studies revealed that
the PDGF family members are also produced by epithelial and endothelial cells. Given
that PDGF is a potent mitogen for mesenchymal cells, PDGF family members are
reported to play a role in chemotaxis, cell survival, transformation, and apoptosis (190).
The PDGFs are known to induce cell migration, proliferation, and transformation. As
such, PDGF plays an important role in vivo in embryonic development, wound healing,
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and inflammation. The PDGF ligands are secreted from cells as either homodimers or the
heterodimer AB. Unlike the classic PDGF ligands, A and B, the recently discovered
PDGF C and D are secreted from the cells in a latent form, requiring proteolytic removal
of the N-terminal CUB (C1r/s, Uegf, and bone morphogenic protein-1) domain in order
to activate the !- or "-PDGF receptors (PDGFRs), respectively.
The PDGF family consists of four members: the classical ligands A and B, and
the newly discovered ligands C and D. Distinct chromosomes encode each PDGF ligand,
with PDGF A at 7p22, PDGF B at 22q13, PDGF C at 4q31, and PDGF D at 11q22. Four
dimers are known to exist, the homodimers AA, BB, CC, and DD, and the heterodimer
AB. The PDGF family is characterized by eight conserved cysteine residues. These
cysteine residues allow for intra- and interchain disulfide bonds to create dimers.
Intrachain disulfide bonds are formed between the 1st and 6th, 3rd and 7th, and 5th and 8th
cysteines, whereas the 2nd and 4th cysteines are responsible for the interchain disulfide
bridges. However, PDGF D lacks the fifth conserved cysteine residue. Previous studies of
PDGF B have shown that the bonds between the 1st and 6th as well as between the 3rd and
7th cysteine residues are essential for PDGF B activity, but the bonds between the 5th and
8th cysteine residues are not (47, 125, 143). Therefore, it is likely that the lack of the 5th
conserved cysteine in PDGF D does not critically impact the function of the protein.
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Fig. 1. PDGF Family. The PDGF ligands dimerize and activate their respective
receptors, as depicted.
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1.3 PDGF Receptors
The PDGF ligands bind to and activate two membrane-bound receptors, !- and "PDFGR. PDGF-AA activates the homodimer PDGFR-!!; PDGF-BB activates
homodimers PDGFR-!! and -"", as well as the heterodimeric receptor PDGFR-!";
PDGF-AB is able to activate either PDGFR-!! or -!". PDGF-CC is able to activate
PDGFR-!! and –!", and PDGF-DD preferentially activates PDGFR-"" (Fig.1).
Although PDGF C and D exhibit a great deal of homology to VEGF, the PDGF ligands
are unable to activate the VEGF receptors (13).
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The PDGF receptors are class III receptor tyrosine kinases, consisting of an

extracellular region, made up of five immunoglobulin-like domains, a transmembrane
region, and an intracellular region, made up of the splitted kinase domains, a kinase insert
domain, and a cytoplasmic tail. !- and "-PDGFR exhibit a high degree of homology in
the two halves of the kinase insert domain, sharing 85% and 75% identity between the
two isoforms. The remaining regions of the receptors, however, have less similarity; the
ligand binding domain, kinase insert, and C-terminus are only 31%, 27%, and 28%
homologous, respectively (112, 138).
Upon activation of the PDGF receptors, dimerization and autophosphorylation of
tyrosine residues occurs. Signal transduction molecules that contain SH2 domain, such as
PLC-!, RAS-GAP, PI3K, Grb 2, Shc, and Src, interact with the phosphorylated tyrosine
residues on the receptors (30). This interaction leads to signal transduction through
intracellular signaling molecules such as Akt, MAPK family members, and focal
adhesion kinase (FAK) (30). This PDGF/PDGFR signal transduction pathway leads to
induction of cell growth, proliferation, migration, cell survival, and transformation.
Interestingly, !- and "-PDGFR are able to stimulate distinct downstream signaling
molecules with different affinities. For example, "-PDGFR but not !-PDGFR is able to
bind and activate Ras-GAP, whereas !-PDGFR but not "-PDGFR exhibits a high affinity
for Crks (190). Additionally, !- and "-PDGFR differentially activate MAPK pathways;
although both receptors activate ERK, !-PDGFR but not "-PDGFR activates JNK-1,
(189). ERKs are mitogenic and therefore associated with cell proliferation, whereas JNK
is associated with cell cycle arrest; thus, activation of !-PDGFR antagonizes the
transformative effects of "-PDGFR, as previously shown by our lab (189).
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1.4 PDGF C and PDGF D
For approximately thirty years. PDGF A and B were thought to be the sole
ligands for !- and "-PDGFR. However, studies of PDGF/PDGFR knockout mice
revealed that loss of either !- or "-PDGFR resulted in phenotypes that were not
completely recapitulated with the loss of either or both PDGF A or B, suggesting the
existence of additional ligands. A BLAST search of the expressed-sequence tag databases
at the National Center for Biotechnology Information uncovered two new PDGF ligands,
PDGF C and D (13, 82, 92). These newly identified ligands contain the core
PDGF/VEGF domain shared by PDGF A and B; however, they also contain an additional
N-terminal CUB domain. This CUB domain, consisting of approximately 110 amino
acids, is similar to the CUB domains found in the complement subcomponents C1r/C1s,
Uegf, and bone morphogenetic protein 1 (17). PDGF C and D consist of 345 and 370
amino acids, respectively, and are approximately 50% homologous in the PDGF/VEGF
domain, while they are only ~20-23% homologous to PDGF A and B (13). PDGF D is a
highly conserved protein, with the human and murine versions sharing approximately
85% similarity of their amino acids (82).
In the developing mouse (embryonic day 14.5), immunohistochemistry revealed
PDGF D expression is highest in the developing heart, kidney, and lung (13). Northern
blotting analysis of adult human tissue revealed that PDGF D is highly expressed in the
heart, ovary, stomach, bladder, and mammary gland (13, 82). Interestingly, PDGF D is
expressed at high levels in the adrenal gland, pancreas, and testis, where little to no
PDGF B is detected by real time PCR, suggesting a distinct requirement for different "-
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PDGFR ligands in specific tissues (82). It is possible that the distinct expression of PDGF
D but not PDGF B in certain tissues is due to the ability of PDGF D to stimulate cells that
express either !-PDGFR or both "- and !-PDGFR without stimulating nearby cells that
express only "-PDGFR. Additionally, PDGF D has been shown to be expressed by the
adventitial connective tissue layer of the suprarenal artery (171). Given that the arterial
smooth muscle cells (SMC) have previously been shown to express !-PDGFR, this
localization of PDGF D suggests a method for paracrine signaling to stimulate SMCs.
1.5 Activation of PDGF D
Unlike the classical PDGF ligands A and B, PDGF-C and –D are produced with
an N-terminal CUB domain in addition to the C-terminal PDGF/VEGF domain. When
secreted by the cell, the dimeric forms of PDGF C and D (PDGF CC and PDGF DD,
respectively) are inactive. The CUB domain must be proteolytically removed from the
latent full-length form to release the growth domain in order for the protein to activate
PDGFR. It has been suggested that this requirement for removal of the CUB domain
serves as a method of regulation of PDGF C or D activity by cells expressing proteases
capable of cleaving the CUB domain (82). Previous research has indicated that PDGFCC is processed by tissue plasminogen activator (tPA), whereas PDGF-DD can be
activated by urokinase plasminogen activator (uPA) (41, 169). However, as discussed in
more detail later in this paper, it is likely that PDGF-DD can be processed into its growth
domain by another protease aside from uPA; PDGF-DD is also a substrate for the
protease matriptase (manuscript submitted). Matriptase processes PDGF D in a multi-step
manner; first, the CUB domain is removed through cleavage at R247GR249S, creating a
PDGF DD dimer consisting of one full length PDGF D monomer and one growth factor
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CUB

PDGF

FL-D
CUB

PDGF

referred

to

as

a

hemidimer.

Subsequently, matriptase cleaves the
second CUB domain from the dimer,
releasing the active PDGF DD dimer.

HD
CUB

PDGF
PDGF

Additionally, matriptase can further
deactivate PDGF DD by cleaving within
the

growth

factor

domain

at

R340R341GR343, resulting in an inactive

PDGF
PDGF

p18/p18
GD-D

PDGF DD dimer (Fig. 2).
1.5A Matriptase, an Epithelial
Cell

Specific

Serine

Protease.

Matriptase (also known as MT-SP1 or

PDGF
PDGF

p15/p15
GD-D

TAGD-15), encoded by the St14 gene,
is a type II transmembrane serine
protease,

Fig. 2. Processing of PDGF DD. The full
length PDGF DD dimer is proteolytically
activated by matriptase in a two step
manner; first, one CUB domain is cleaved,
resulting in a hemidimer, followed by the
removal of the second CUB domain to
result in the active p18/p18 PDGF DD
growth factor domain dimer. Subsequent to
its activation, matriptase deactivates PDGF
DD into an inactive p15/p15 dimer. FL-D:
Full length dimer; HD: Hemidimer; GD-D:
Growth domain dimer.

consisting

of

a

short

intracellular N-terminal domain and a
transmembrane domain, followed by
one SEA (sperm protein, enterokinase,
and agrin), two CUB, and four LDLRA
(low density lipoprotein receptor class
A) domains, in addition to the Cterminal serine-protease domain. First
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identified in human breast cancer cells, matriptase has subsequently been found to be
produced by many epithelial tissues, including the epidermis, intestines, prostate, breast,
and ovaries (101, 122). This epithelial cell specific protease has previously been shown to
activate uPA, protease-activated receptor 2 (PAR2), hepatocyte growth factor (HGF), and
profilaggrin (87, 103, 160). Additionally, matriptase is regulated by its cognate inhibitor,
HGF activator inhibitor (HAI)-1 (HAI-1) (95). This regulation of matriptase function is
brought about through regulation of expression, activation, and trafficking (76, 86, 123).
Although, paradoxically, HAI-1 has been traditionally thought to be required for
matriptase activation, recent studies have suggested that matriptase can be activated in
the absence of HAI-1 (32, 73, 114).
Matriptase has been shown to be critical in the regulation of the epithelial barrier
and permeability of the intestines, as loss of the protease resulted in decreased
transepithelial electrical resistance and increased permeability (19). Similarly, loss of
matriptase is perinatally lethal due to skin permeability defects that lead to dehydration
(100). Mice that exhibit a 100-fold reduction in epidermal matriptase expression display
symptoms similar to the human disease autosomal recessive ichthyosis with hypotrichosis
(ARIH) (99). The skin of these mice display ichthyosis, or scaly skin, along with thin
whiskers, patchy and uneven fur, tooth defects, and a hyperproliferative epidermis with
an impaired barrier function. Accordingly, patients with ARIH exhibit a missense
mutation of G827R in the catalytic region of matriptase (10). Increased expression of
matriptase in the skin has also been studied with a transgenic mouse model (102). In
these mice, matriptase expression was driven by the keratin-5 promoter. Thus, matriptase
was overexpressed in keratin-5-expressing tissues such as the epidermis. Matriptase
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transgenic mice exhibited interfollicular hyperplasia, epidermal dysplasia, follicular
transdifferentiation, dermal fibrosis, and inflammation. Increased expression of
matriptase in the skin lead to the spontaneous development of epidermal neoplasias in
100% of mice, and the formation of squamous cell carcinoma in 70% of transgenic mice.
A single treatment of DMBA was sufficient to induce tumor formation in 95% of
matriptase transgenic mice, as compared to just 1.7% of wild type mice. The
matriptase/DMBA-induced tumors in these mice were capable of invading through the
dermis, adipose, and muscle, and lead to metastatic disease in 25% of cases. Thus,
matriptase has been shown to have a potent oncogenic potential.
Matriptase has been shown to be overexpressed in mesothelioma as well as
cervical, ovarian, breast, esophageal, liver, and prostate cancers (25, 61, 70, 85, 121, 136,
141, 142, 162, 164, 165). Although matriptase expression is associated with cancer
development and progression, little is known as to the mechanism of the association
between matriptase and cancer. Thus, further investigation of the activation of PDGF D
by matriptase may help to elucidate the role of the matriptase/PDGF D/!-PDGFR
signaling axis in oncogenesis.
1.6 Roles of PDGFs
PDGFs are known to stimulate cell proliferation, chemotaxis, survival, and
transformation. PDGF has also been shown to be involved in inflammation and wound
healing. Additionally, PDGFs are able to control the expression of collagen, collagenase,
proteoglycan, hyaluronic acid, and fibronectin, suggesting that PDGFs play a role in
tissue remodeling (16, 20, 28, 54, 117, 145). PDGFs have been shown to play a role in
fibroproliferative diseases in organs such as the kidneys and lungs, as well as in plaque
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formation during atherosclerosis. PDGFs also have pro-angiogenic effects, as activation
of !-PDGFR on endothelial cells results in recruitment of pericytes to immature blood
vessels [reviewed in (6, 55)].
Many studies have been performed looking at the loss of PDGF ligands and their
receptors through use of knockout or transgenic mice. These studies have helped to
elucidate the functions during embryogenesis, as loss of PDGF A, PDGF B, PDGF C, "PDGFR, or !-PDGFR results in either embryonic or perinatal death. "-PDGFR knockout
mice die between E8 and E16 (154). Lethality was shown to be due to skeletal defects,
spina bifida, and cleft face. Additionally, mice engineered to express "-PDGFR with the
activating mutation D842V die at day E12.5 due to hemorrhage in both the abdomen and
pericardial cavity. The phenotype was determined to be caused by an enlarged dorsal
aorta with disorganized vasculature and a decrease in vascular smooth muscle cells. In
addition, these mice also exhibited improper folding of the neural tube due to a lack of
mesenchymal cells (78). Loss of !-PDGFR is also embryonically lethal, due to
malformations in both the kidneys as well as blood vessels (96, 153). Additionally,
increased expression of an autoactivated !-PDGFR is also embryonically lethal, due to
defects in the formation of the placenta and fetal blood vessels (107).
Mice lacking PDGF A exhibit defective pulmonary alveoli development, in
addition to skin and brain defects, leading to death between embryonic day 10 (E10) and
shortly after birth (18, 42). Loss of PDGF B causes kidney defects and cardiovascular
defects caused by a lack of pericyte migration to new blood vessels. These PDGF B
deficient mice die during late gestation (90, 97). PDGF C knockout mice die shortly after
birth due to difficulty breathing and feeding brought about by secondary palate defects
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(35). Given that this phenotype closely resembles that of the !-PDGFR knockout mice, it
is likely that PDGF C plays a larger role than PDGF A in !-PDGFR signaling during
embryogenesis.
Unfortunately, no PDGF D knockout mouse has been reported to date, although
one model is in development (4). Thus, the role of PDGF D in embryogenesis has yet to
be determined. However, given that PDGF B and "-PDGFR knockout mice exhibit
similar phenotypes, it is likely that PDGF D does not play a large role during
embryogenesis. It remains to be seen, though, what role PDGF D / "-PDGFR signaling
plays subsequent to embryonic development. PDGF D has, however, been conditionally
overexpressed in the heart (131). In these mice, PDGF D expression was driven by the
heart-specific !-myosin heavy chain promoter. Heart-specific PDGF D transgenic mice
developed many abnormalities in heart physiology, including enlarged hearts and cardiac
fibrosis, which contributed to heart failure and death of the mice. Additionally, PDGF D
expression lead to dilation of the blood vessels, vascular remodeling, thickening of blood
vessel walls, proliferation of arterial smooth muscle cells. Interestingly, while PDGF B is
expressed only in endothelial cells of capillaries (56), PDGF D was found to be
colocalized with "-PDGFR on arterial vascular smooth muscle cells, suggesting that the
two ligands may play different roles in the vasculature.
1.7 PDGFs in Cancer
PDGF family members have been shown to play a potential role in cancer
development and progression. The correlation between PDGF and cancer was first
indicated by the fact that PDGF-B shares a 92% homology with the oncogenic v-sis.
Subsequently, PDGFs and their receptors have been found to be upregulated in numerous
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cancers, as listed in Table 1. Given that PDGFs play a key role in angiogenesis, the
PDGF ligands and receptors can also promote tumor growth through the promotion of the
development of tumor vasculature. PDGFs have also been shown to regulate the
differentiation of stromal mesenchymal cells into osteoprogenitor cells, thus potentially
having a role in bone metastases. PDGF D specifically has been shown to be associated
with human glioblastoma, medulloblastoma, lung cancer, and ovarian cancer (81, 105).
PDGF D has also been found to be expressed in human breast adenocarcinoma, alveolar
cell carcinoma, prostate adenocarcinoma, renal cell carcinoma, Wilms tumor, and
erythroleukemia cell lines (171).
The mechanism by which the ligands and receptors are associated with cancer varies
according to the type of cancer. For example, !-PDGFR has been found to be
upregulated in glioblastoma due to gene amplification; autoactivating mutations of !PDGFR are also associated with gastrointestinal stromal tumors (GIST) (53). Chronic
myelomonocytic leukemia is commonly associated with a constitutively active form of "PDGFR due to fusion of the kinase domain of the receptor with the promoter of the TEL
gene, a member of the ets family (48).
Importantly, our lab has shown that in a mouse model, LNCaP cells transfected with
PDGF D exhibit accelerated onset of prostate tumor growth as well as drastically
enhanced prostate carcinoma cell invasion into surrounding stromal cells, demonstrating
a potential oncogenic activity of PDGF D in the development and/or progression of
prostate cancer (170).
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Cancer Type
Breast

Method of Detection
IHC

PDGF/R Isoform
PDGF B, !-PDGFR

Choriocarcinoma
Colorectal
adenocarcinoma
Dermatofibrosarcoma
Esophageal
Ewing family
sarcomas
Gastrointestinal
stromal tumors
Glioma

ISH, IHC
IF, IHC

PDGF B, "-PDGFR
PDGF B, !-PDGFR

Ref.
(22, 66, 146,
185)
(63)
(98, 159)

FISH, Southern blot,
Northern blot, RT-PCR
Northern blot
IHC, RT-PCR,
Northern blot
Western blot,
Mutational analysis
ISH, IHC, Northern
blot

PDGF B

(120, 149)

PDGF A, B, PDGFR
PDGF C, "-PDGFR

(186)
(168, 194)

!-PDGFR

(53)

PDGF A, B, D, !-, "PDGFR

Kaposi’s sarcoma
Lung

PDGF A, B, "-PDGFR
PDGF B, D, "-PDGFR

Melanoma

ISH, IHC
ISH, IHC, Real time
PCR, ELISA
Northern blot

(59, 105, 110,
118, 119, 130,
180)
(156)
(5, 71, 81)

Myelomonocytic
leukemia
Neurofibroma
Osteoblastoma
Osteosarcoma
Ovarian

FISH, Northern blot,
Southern blot
IHC, RT-PCR
IHC
IHC
IHC, ELISA

Prostate

IHC, Microarray

PDGF A, B, !-, "PDGFR
"-PDGFR

(77, 137)

"-PDGFR
PDGF A, !-PDGFR
PDGF A, !-PDGFR
PDGF A, B, D, !PDGFR
PDGF A, !-, "-PDGFR

(69)
(157)
(93, 157)
(58, 81)

(48)

(44, 62, 74,
129, 135, 147,
150, 152)
(29)
(126, 178)

Stomach
ISH, IHC
PDGF B
Soft tissue tumors ISH, IHC
PDGF B, "-PDGFR
!
"#$%&! '(! Literature review of PDGF/R association with cancer. ISH: In situ
hybridization; IF: Immunofluorescence; FISH: Fluorescence in situ hybridization; IHC:
Immunohistochemistry; RT-PCR: Reverse transcription polymerase chain reaction;
ELISA: Enzyme-linked immunosorbent assay.
!
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1.8 PDGFs in Prostate Cancer
Prostate cancer is the most diagnosed non-cutaneous cancer of men in the United
States, and the second leading cause of cancer-related mortality, accounting for 10% of
Marker
PDGF D
!-PDGFR
Matriptase

Metastatic Studies
No. Upregulated/Total (%)
3/4 (75%)
3/5 (60%)
5/5 (100%)

!
"#$%&!'(!)*+,-#-&!.#/.&*!.012!
34.*+#**#5!&67*&,,4+/!7*+84%&(!

cancer-related mortality among men
(67). Previous studies have found that
!-PDGFR is upregulated in prostate
cancer, with 80% of both primary and
metastatic prostate cancer expressing

!-PDGFR (74). Importantly, expression of !-PDGFR has been identified by microarray
as part of a five-gene model, along with chromogranin A, HOXC6, IPTR3, and
sialyltransferase-1, that is able to predict prostate cancer recurrence (150). PDGF B,
originally thought to be the sole ligand for !-PDGFR, is not detected in prostate cancer
(PCa) (43, 44, 62, 74). As discussed below, PDGF D, which is also able to activate !PDGFR, is upregulated in PCa, as shown by immunohistochemistry (manuscript in
preparation). Confirming these results, a search of microarrays performed on metastatic
prostate cancer samples compiled in the Oncomine database (Compendium Biosciences)
revealed an upregulation of PDGF D and !-PDGFR as well as matriptase in the majority
of cases, with increased expression in 75%, 60%, and 100%, respectively, of metastatic
samples relative to localized prostate cancer (Table 2) (33, 79, 80, 108, 172, 173, 191).
However, no previous studies have elucidated the mechanism that resulted in the switch
between PDGF B and PDGF D/!-PDGFR expression in prostate cancer.
In a mouse model in which LNCaP-PDGF D cells were injected subcutaneously,
PDGF D expression accelerates early onset of prostate tumor growth, and drastically
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enhances prostate carcinoma cell invasion into surrounding stromal cells, demonstrating a
potential oncogenic activity of PDGF D in the development and/or progression of
prostate cancer (170). Additionally, in mice that were injected intratibially with the
prostate cancer cell line PC-3MM2, the receptor tyrosine kinase inhibitor Gleevec
(STI571, imatinib mesylate), which inhibits Bcr-Abl, PDGFR, and c-Kit, was shown to
reduce tumor incidence and growth, and an increase in apoptosis in the tumor cells as
well as tumor associated endothelial cells (167). Thus, a growing body of evidence
suggests that the PDGF/PDGFR signaling pathway plays a role in prostate carcinoma.
1.9 PTEN/PI3K/Akt Pathway
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN, also
known as MMAC1/TEP1) is a lipid and protein phosphatase. Its key role is to serve as a
negative regulator of the phosphatidylinositol-3 kinase (PI3K) pathway [reviewed in
(23)]. PI3K family members are categorized as class IA, IB, II, or II. Class IA PI3Ks
consist of heterodimers composed of a catalytic subunit (p110!, p110", or p110#) and a
regulatory subunit (p85!, p85", or p55#). When cells are stimulated with growth factors,
class IA PI3Ks generate phosphatidylinositol 3,4,5-triphosphate (PIP3) through
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2). PIP3 is then able
recruit proteins that contain pleckstrin homology domains, such as the serine/threonine
kinase Akt/PKB, to the plasma membrane. Subsequent to phosphorylation, Akt is able to
phosphorylate its downstream targets such as BAD, GSK3, FOXO, MDM2, NF$B, and
TSC2. PTEN has also been shown to inhibit MAPK and FAK pathways (51, 161).
Through its attenuation of the PI3K pathway, PTEN is able to regulate key cellular
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processes such as cell proliferation, motility, protein synthesis, glucose metabolism,
genomic stability, and survival.
1.10 PTEN in Cancer
Also known as MMAC (mutated in multiple advanced cancers), PTEN is located
on chromosome 10q23 (91, 155). Mutations of PTEN are associated with several
diseases, including Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana
syndrome (94, 111). In addition, loss of PTEN has been shown to be associated with
many types of cancer, such as glioblastoma, endometrial carcinoma, and breast cancer.
As shown in Table 3, previous studies have found that PTEN is lost or mutated in 7080% of primary prostate cancer, and 50% of prostate cancer bone metastases. In mouse
models, it has been shown that loss of PTEN is critical for tumor initiation, and the level
of PTEN expression is inversely associated with prostate tumorigenesis (34, 163).
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(49)

(39)
(127)
(50)
(124)
(140)
(36)
(83,
138)
(89)
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Method of PTEN
Detection
PCR, allele typing,
SSCP, sequencing
LOH analysis w/
PCR, SSCP,
sequencing
PCR for microsatellite
markers
Mutation analysis,
Northern analysis
LOH, FISH,
Sequencing
LOH
SSCP, direct DNA
sequencing
LOH, microsatellite
instability, SSCP,
PCR

(174)

LOH, CGH, SSCP
Array-based CGH,
FISH, SSCP, IHC

(188)

FISH, IHC

(144)

Multiplex PCR-based
microsatellite analysis

(187)

FISH

(133)

SSCP

(79)
(111,
113)

Array CGH, FISH

(151)
(65)

FISH, IHC
IHC, FISH, SNP
Array Analysis
Array CGH, FISH

Findings
Tumor suppressor gene near the 10q23-24 boundary was deleted
in 96% of tumors

LOH in 49% of primary PCa
LOH in 55% and mutation in 17% of primary PCa
5 PTEN mutations identified; 70% of tumors had loss or
alteration of at least 1 allele
LOH in 11% of Japanese patients with PCa
LOH in 14% node negative PCa, 43% node positive PCa;
10q23.3 is a marker for progression
PTEN mutated in 16% of Chinese patients with primary PCa,
33% of American patients with metastatic PCa
Frequent alterations linked to late stage PCa; microsatellite
instability was increased in adenocarcinomas
LOH at the PTEN gene is frequent but mutations in the
remaining allele were not detected by SSCP-screening
Bi-allelic deletion is a major mechanism of PTEN inactivation
in locally progressive PCa
Deletions were found in 3/13 (23%) of high-grade PIN and
24/35 (68%) of PCa
LOH observed in 85% of prostate cancer cases; PTEN
associated with the occurrence of circulating tumor cells as well
as a sign of early biochemical recurrence
Hemizygous PTEN loss present in 39% of prostatic
adenocarcinomas, with a homozygous PTEN deletion observed
in 5% tumors
Patients w/ PCa who had PTEN mutation had also a
significantly greater Gleason score, poorer prognosis, and higher
rate of metastasis
PCa develop via a limited number of alternative preferred
genetic pathways, including loss at 10q23 (PTEN)
Heterogeneous PTEN gene deletion was observed in 23% of
hormone sensitive tumors, 52% of hormone-refractory tumors
PTEN deleted in 77% of PCa cases
25% of intermediate-risk group exhibits deletion of PTEN

Table 3. Literature review of PTEN expression in prostate cancer. PCR: polymerase
chain reaction; SSCP: Single strand conformation polymorphism; LOH: Loss of
heterozygosity; FISH: Fluorescence in situ hybridization; CGH: Comparative genomic
hybridization; IHC: Immunohistochemistry; SNP: Single nucleotide polymorphism.
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1.11 PTEN Mouse Models
Loss of PTEN throughout the mouse is embryonically lethal, as embryonic stem
cells lacking Pten form aberrant embryoid bodies and are unable to properly differentiate
into ectoderm, mesoderm, and endoderm (34). Thus, heterozygous as well as tissue
specific knockout models were developed to study the effects of PTEN expression.
Pten+/- mice develop hyperplasia of the prostate as well as spontaneous colon and thyroid
carcinomas (34). In order to study the role of PTEN in prostate carcinoma, a prostate
specific Pten knockout mouse model was developed using the Cre/Lox system. In this
model, Cre recombinase expression was driven by the androgen responsive, prostate
specific probasin promoter, while exon 5 of Pten was flanked by LoxP sequences (88,
182). Upon expression of androgens, Cre recombinase is expressed specifically in the
prostate, and recognizes the LoxP sequences in the PTEN gene and eliminates the
sequnce flanked by LoxP. Exon 5 is critical for the phosphatase activity of PTEN. Thus,
exon 5 of Pten is deleted, rendering the resulting protein inactive. In this system, Pten+/mice develop mPIN lesions (mouse prostate intraepithelial neoplasia) at 12-16 months;
however, no progression to carcinoma was observed. Pten-/- mice, however, developed
mPIN at the age of six weeks, followed by adenocarcinoma at 9 weeks (14, 15). Thus,
this prostate specific loss of PTEN recapitulates human prostate carcinoma.
1.12 The Serine/Threonine Kinase Akt
The Akt family of serine/threonine kinases consists of three isoforms:
Akt1/PKB!, Akt2/PKB", and Akt3/PKB/!. Once recruited to the plasma membrane, Akt
is activated through phosphorylation of two regulatory sites. Thr308/Thr309/Thr305 (in
Akt1/Akt2/Akt3, respectively), in the P-loop of the protein kinase domain, is
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phosphorylated by PDK1; Ser473/Ser474/Ser472 (in Akt1/Akt2/Akt3, respectively), in
the carboxy-tail region, is phosphorylated by mTORC2 (1). Phosphorylation of the
threonine site is required for activation, although phosphorylation of the serine site is
required for maximal activity (37, 57).
Many studies have shown that the Akt isoforms have compensatory functions,
although the individual isoforms also play non-redundant roles. Although little is known
regarding the distinct mechanism as to how each isoform regulates different cellular
processes, knockout mouse models have established unique roles of each Akt isoforms, in
which the phenotypes seen in mice lacking one Akt isoform are not compensated for by
the remaining two isoforms [reviewed in (184)]. Loss of Akt1 leads to decreased
vascularization and size of the placenta, as well of a lack of differentiation of
trophoblasts. The placental defects caused by the loss of Akt1 results in decreased birth
weight and increased infant mortality (27). Mice lacking Akt2 develop severe diabetes
due to impaired glucose metabolism (26, 46). It was later discovered that stimulation of
the PI3K pathway by insulin results in activation of Akt2, which in turn is critical for the
translocation of GLUT4 to the plasma membrane (60). Therefore, mice lacking Akt2 are
unable to transport glucose into the cell upon insulin stimulation. Akt3 knockout mice
exhibit a 20-25% decrease in brain size, brought about by both decreased cell size as well
as cell number (38, 166).
Akt has also been linked to prostate cancer. As shown through immunostaining
Akt that is phosphorylated at Ser473, prostate tumors exhibit increased activation of Akt
(158). Additionally, mice that overexpress constitutively active Akt1 specifically in the
prostate develop mPIN, with hyperplasia, dysplasia, and intraepithelial lumen formation,
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leading to bladder obstruction, similar to the phenotype seen in Pten+/- mice (109).
Interestingly, studies of the prostate cancer cell lines DU145, PC3, and LNCaP have
shown that, while Akt1 and Akt2 are uniformly expressed, Akt3 expression is
upregulated in the androgen-insensitive DU145 and PC3 as compared to the androgen
responsive LNCaP cell line. Akt3 enzymatic activity was also 20-40 fold higher in
DU145 and PC3 as compared to LNCaP (116). Given the role of Akt in promoting cell
survival and proliferation, it is possible that this increased expression and activity of Akt3
could contribute to the aggressive nature of androgen-insensitive prostate carcinoma.
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Chapter 2
Materials and Methods

2.1 Cell Culture. All cell lines were cultured at 37°C in a humidified incubator with 5%
CO2, and all media was supplemented with 2mM glutamine, 100units/ml penicillin and
100mg/ml streptomycin (Life Technologies Inc., Carlsbad, CA).

Human prostate

carcinoma cell lines and resultant transfectant cell lines (170), (169) were maintained in
RPMI 1640 supplemented with 5% fetal bovine serum. Prostate specific Ptenlox/+
(referred to hereafter as Pten+/+), Pten+/-, and Pten-/- mice were established as previously
described (14). Pten-/-, Pten+/-, and Pten+/+ mouse prostate epithelial cells were isolated
from anterior prostates of 8-10 week-old corresponding mice (15) using the method
previously described (9). Ptenlox/lox cells were isolated from anterior prostates of 8 weekold mice. In vitro deletion of Pten was achieved by infecting Ptenlox/lox cells with a selfdeleting Cre-recombinase lentivirus (128). Cells were clonally selected using serial
dilution method (8) and Pten status was confirmed by genotyping and Western blotting.
Cells were maintained in Advanced DMEM supplemented with 5% FBS, 2mM
glutamine, 100units/ml penicillin, and 100mg/ml streptomycin.
2.2 Reagents. Generation of antibody that recognizes the growth domain of PDGF D was
described previously (169, 170). Anti-matriptase antibodies M32 and S5 were
characterized

and

described

previously

(95).

Antibodies

recognizing

PTEN,

phosphorylated !-PDGFR and phosphorylated Akt were purchased from Cell Signaling
Technology. Akt1, Akt2, and Akt3 antibodies were purchased from Upstate.
2.3 Microarray. Stably transfected cell lines LNCaP-neo (vector control) and LNCaPPDGF D were cultured in 150mm plates, and total RNA was extracted using 3mls of
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Trizol Reagent per 150mm plate. Total RNA from 6 plates were pooled together to make
a master stock for each cell line. Total RNA was purified further using the RNeasy Kit
(Qiagen, Valencia, CA). A quality check of the total RNA was performed using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The Bioanalyzer was
used to determine if the 18S and 28S ribosomal bands are defined and to ensure no RNA
degradation was present. The RNA samples were also analyzed with a spectrophotometer
and 260/280 ratio in the range of 1.9-2.2 were defined as acceptable. After determination
of quality, 10 µg of RNA for each sample was reverse transcribed and labeled with
Cyanine 5. Stratagene’s Universal Human reference RNA (Stratagene, La Jolla, CA) was
used as a reference sample and was labeled with Cyanine 3. Agilent’s fluorescent direct
labeling kit (Agilent Technologies) was used to synthesize the labeled cDNA. The
labeled cDNA was purified using QIAquick PCR Purification kit from Qiagen (Qiagen,
Valencia, CA). The Cyanine 3 and Cyanine 5 samples were mixed together and allowed
to co-hybridize on the array for 17 hours at 65°C. Each sample was run in triplicate
against the reference sample. The arrays used are Agilent’s Human 1 cDNA Microarrays
(Agilent Technologies) with 12,814 unique human clones on each array. After
hybridization the microarrays were washed and dried according to Agilent's cDNA
microarray hybridization protocol. Slides were immediately scanned with the Agilent
dual laser scanner. The photo multiplier tube (PMT) settings were set at 100% for both
channels. Tiff images were analyzed using Agilent’s feature extraction software to obtain
fluorescent intensities for each spot on the arrays. LOWESS normalization was
performed on the intensity values. ANOVA analysis and clustering was performed using
Rosetta Resolver software (Rosetta Biosoftware, Kirkland, WA). Differential gene
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expression between the LNCaP-neo and LNCaP-PDGFD:HIS samples of each cell line
was identified by selecting genes with an ANOVA p-value < 0.01.
2.4 Immunohistochemical Analysis of PDGF D, Matriptase, and Phosphorylated !PDGFR in Human and Murine Tissue. Slides of sixty-six formalin fixed, paraffinembedded human prostate specimens, including sections of benign, benign prostatic
hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and prostate carcinoma, were
obtained from the Wayne State University Pathology Research Core Facility. Murine skin
sections from wild type, matriptase transgenic, and matriptase/HAI-1 transgenic mice
were obtained courtesy of Dr. Thomas Bugge of the NIH. Pten+/+ and Pten-/- prostate
tissue sections were obtained courtesy of Dr. Yong Q. Chen of Wake Forest University.
Tissue slides were deparaffinized with xylene, then rehydrated sequentially with
decreasing concentrations of EtOH from 100% to 70%, followed by water. Antigen
retrieval was performed by steaming for twenty minutes in a sodium citrate buffer.
Slides were then washed twice with PBS and blocked with Cas-Block solution (Zymed).
Endogenous peroxidase activity was blocked with 3% H2O2. Slides were incubated
overnight at 4ºC in a humidified chamber with either anti-PDGF-D polyclonal Ab
(custom antibody 8D2, 1:300 dilution), anti-matriptase monoclonal Ab (custom antibody
S-5, 1:3000 dilution), or anti-phosphorylated !-PDGFR polyclonal Ab ($%&&! '()*+&(*)!
,%-.*/&/)01!23456. Sections were then washed twice with PBS and incubated with ABC
Vectastain Kit (Vector Labs) according to manufacturer’s protocol, followed by
incubation with 3,3’-diaminobenzadine tetrahydrochloride (DAB, Vector Labs). Mayer’s
hematoxylin was used to counterstain the nuclei (Sigma-Aldrich). Sections were then
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dehydrated with increasing concentrations of EtOH and washed with xylene twice, and
mounted with Permount (Fisher Scientific).
2.5 Statistical Analysis. Immunohistochemistry of tissue sections were analyzed by uropathologist Dr. $%&'(%&! Che, in which a blind assessment of the percentage of tumor
cells positive for PDGF D or matriptase was analyzed for semi-quantitation. Statistical
analysis was performed by biostatistician Dr. Judith Abrams using Kendall’s tau analysis
to assess the association between the American Joint Committee on Cancer (AJCC)
tumor stage and Gleason score with PDGF-D and matriptase staining. In this method, a
coefficient value of 1 indicates a perfect direct correlation and a coefficient value of -1
indicates a perfect inverse correlation, while a coefficient value of 0 indicates no
correlation.
2.6 In Situ Hybridization. Digoxigenin-labeled antisense probes were synthesized from
pCR2.1-PDGF D using the DIG RNA Labeling Kit (Roche Applied Science) according
to the manufacturer’s instructions. PDGF D sense probes, created with pcDNA3.1-PDGF
D, were used as a negative control. Paraffin embedded sections of human prostate
carcinoma were deparaffinized with xylene followed by serial dilutions of ethanol. Slides
were treated with prehybridization solution for 1hr at 65ºC, then incubated with either
PDGF D antisense or sense probes overnight at 65ºC. After blocking with CAS-Block
solution (Zymed), the probe was detected using anti-digoxigenin antibodies and
visualized using 3,3’-diaminobenzadine tetrahydrochloride (DAB, Vector Labs). The
sections were then dehydrated with serial dilutions of ethanol, washed with xylene, and
mounted with Permount.
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2.7 Immunofluorescent Double Staining of Matriptase and PDGF D in Human
Prostate Tissue.

For immunofluorescent staining, slides were deparaffinized with

xylene, and double probed with anti-PDGF D rabbit polyclonal antibody and antimatriptase mouse-monoclonal antibody M32. Texas Red-conjugated-anti-mouse and
FITC-conjugated-anti-rabbit secondary antibodies were used to detect PDGF D and
matriptase, respectively (Jackson Immunoresearch Laboratories, West Grove, PA).
Confocal immunofluorescence microscopic analysis was performed using a Zeiss LSM
510 confocal microscopy system equipped with a C-Apochromat (NA = 1.2) 63x korr
objective lens (Carl Zeiss MicroImaging, Inc., Thornwood, NY). Images for figures were
colored and resized with associated microscope software available through Wayne State
University Imaging Core Facility.
2.8 !"#$%$&$'"(')(*$+",-$"+(.,&#/,012!$%&&'!(%)%!*+&,+)%-!(.,/!*012&%,%!3)0(,/!
1%-.45!46-!,)%4,%-!(.,/!.6*)%4'.63!*06*%6,)4,.06'!07!.6/.8.,0)'!0)!9%/.*&%!*06,)0&:!
$%&&'!(%)%!,)%4,%-!(.,/!;<=!>6/.8.,0)!>>!?@.'/%)!A*.%6,.7.*B5!CDEFG#E!?A.314!H&-).*/B5!
IJ"EKGG"!?A.314!H&-).*/B5!(0),1466.6!?$4&8.0*/%1B5!0)!HL,!>6/.8.,0)!>M!?@.'/%)!
A*.%6,.7.*B!70)!%.3/,%%6!/0+)':!$%&&'!(%)%!,)%4,%-!(.,/!)4241N*.6!?A.314!H&-).*/B!70)!
KF!/0+)':!1O<H!(4'!*0&&%*,%-!7)01!*%&&'!4,!,/%!-%'.364,%-!,.1%!20.6,!46-!'+8P%*,%-!
,0!OQRC$O!46-!)%4&!,.1%!OQRC$O:!
!
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2.9 RT-PCR. mRNA was purified from cells using the RNeasy kit (Qiagen). cDNA
synthesis was performed with Superscript III First-Strand Synthesis System (Invitrogen),
followed by PCR using GoTaq Flexi DNA Polymerase (Promega). Murine and human
specific forward and reverse primers used are shown in Tables 4 and 5, respectively.
Primer
Sequence
PDGF A forward (F)
5’-TGTGCCCATTCGCAGGAAGAG-3’
PDGF A reverse (R)
5’-TTGGCCACCTTGACACTGCG-3’
PDGF B F
5’-GCCTGTGACTAGAAGTCCTG-3’
PDGF B R
5’-GTCATGGGTGTGCTTAAACT-3’
PDGF C F
5’-TATCTGGTAATGGGAGCATC-3’
PDGF C R
5’-CGTCCTAAAACACTTCCATC-3’
PDGF D F
5’-CAGGGAAGACAGTGAAGAAG-3’
PDGF D R
5’-GAGCTGCAGATACAGTCACA-3’
!-PDGFR F
5’-GTACTTTCCTGCCTGTGAAG-3’
!-PDGFR R
5’-ACTATCTCGCTGAGGTGGTA-3’
!-PDGFR F
5’-CATCATGAGGGACTCAAACT-3’
!-PDGFR R
5’-GATGGCATTGTAGAACTGGT-3’
Matriptase F
5’-AGGTCCCAGTTTGTGGTGAG-3’
Matriptase R
5’-CTCTGAGGGAGACACTT-3’
uPA F
5’-GTGCCGCACACTGCTTCATT-3’
uPA R
5’-CGTGCTGGTACGTATCTTCA-3’
PTEN F
5’-ACACCGCCAAATTTAACTGC-3’
PTEN R
5’-TGAGGTTTCCTCTGGTCCTG-3’
Akt1 F
5’-GACCCACGACCGCCTCTG-3’
Akt1 R
5’-GACACAATCTCCGCACCATAGAAG-3’
Akt2 F
5’-GAGGACGCCATGGATTACAAG-3’
Akt2 R
5’-GACAGCTACCTCCATCATCTCAGA-3’
Akt3 F
5’-GAGTACCTGGCACCAGAGGT-3’
Akt3 R
5’-AGAAAGGCAACCTTCCACAC-3’
GAPDH F
5’-ATCACCATCTTCCAGGAGCGA-3’
GAPDH R
5’-GCCAGTGAGCTTCCCGTTCA-3’
!"#$%&'(&)*+,-%&./%0,1,0&/+,2%+&.%3*%-0%.&*.%4&15+&678(&
2.10 Real time RT-PCR. mRNA was purified from cells using the RNeasy kit (Qiagen).
cDNA synthesis was performed with Superscript III First-Strand Synthesis System
(Invitrogen). Real time RT-PCR was performed using SYBR Green QPCR Master Mix
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(Stratagene) and the Stratagene MX4000 qPCR System according to the manufacturer’s
protocol. Relative values of gene expression were calculated using the 2-!!Ct method,
where !!Ct = (!Cttarget gene " !CtGAPDH)sample " (!Cttarget gene " !CtGAPDH)control. The fold
change in relative expression was then determined by calculating 2-!!Ct.

Primer
Sequence
PDGF A forward (F)
5’-TGAGGATTCTTTGGACACCA-3’
PDGF A reverse (R)
5’-GGGCCAGATCAGGAAGTTG-3’
PDGF B F
5’-CATTCCCGAGGAGCTTTATG-3’
PDGF B R
5’-CTCAGCAATGGTCAGGGAAC-3’
PDGF C F
5’-TCCAGCAACAAGGAACAGAA-3’
PDGF C R
5’-GGGTCTTCAAGCCCAAATCT-3’
PDGF D F
5’-GAACAGCTACCCCAGGAACC-3’
PDGF D R
5’-CTTGTGTCCACACCATCGTC-3’
!-PDGFR F
5’-GAACTCACGGTGGCTGCTG-3’
!-PDGFR R
5’-ACTTTCATGACAGGTTGGG-3’
#-PDGFR F
5’-TTTTGCACCCACAATGACTC-3’
#-PDGFR R
5’-CCAATGGTGGTTTTGCAGAT-3’
Matriptase F
5’-GCACATGGAACATTGAGGTG-3’
Matriptase R
5’-TTCAGCTAAGAAGCCGGTGT-3’
uPA F
5’-CACAGCATTTTGGTGGTGAC-3’
uPA R
5’-TTGCTCACCACAACGACATT-3’
PTEN F
5’-GGACGAACTGGTGTAATGATATG-3’
PTEN R
5’-TCTACTGTTTTTGTGAAGTACAGC-3’
Akt1 F
5’-ATGAGCGACGTGGCTATTGTGAAG-3’
Akt1 R
5’-GAGGCCGTCAGCCACAGTCTGGATG-3’
Akt2 F
5’-ATGAATGAGGTGTCTGTCATCAAAGAAGGC-3’
Akt2 R
5’-TGCTTGAGGCTGTTGGCGACC-3’
Akt3 F
5’-ATGAGCGATGTTACCATTGT-3’
Akt3 R
5’-CAGTCTGTCTGCTACAGCCTGGATA-3’
GAPDH F
5’-ATCACCATCTTCCAGGAGCGA-3’
GAPDH R
5’-GCCAGTGAGCTTCCCGTTCA-3’
!"#$%&'(&)*+",&-.%/010/&.20+%2&-%3*%,/%-&*-%4&152&678(&
2.11 Immunohistochemical analysis of PDGF D in murine prostate tissue. Slides of
formalin fixed, paraffin-embedded prostate sections from Pten+/+ and Pten-/- mice were
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obtained from Dr. YQ Chen at Wake Forest University. Tissue slides were deparaffinized
with xylene, then rehydrated sequentially with decreasing concentrations of EtOH from
100% to 70%, followed by water. Endogenous peroxidase activity was blocked with 3%
H2O2. Antigen retrieval was performed by steaming for twenty minutes in Antigen
Retrieval Citra Plus Solution (BioGenex). Slides were then washed twice with PBS and
blocked with Cas-Block solution (Invitrogen). Slides were incubated overnight at 4ºC in a
humidified chamber with either anti-PDGF-D polyclonal Ab (8D2, 1:500 dilution) or
anti-phosphorylated-!-PDGFR polyclonal Ab (1:100 dilution).

Sections were then

washed twice with PBS and incubated with ABC Vectastain Kit (Vector Labs) according
to manufacturer’s protocol, followed by incubation with 3,3’-diaminobenzadine
tetrahydrochloride (DAB, Vector Labs). Mayer’s hematoxylin (Sigma-Aldrich) was used
to counterstain the nuclei. Sections were then dehydrated with increasing concentrations
of EtOH, washed with xylene twice, and mounted with Permount (Sigma-Aldrich).
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Chapter 3
Results

3.1 Expression of PDGF D and Matriptase in Human Prostate Carcinoma
A. Expression of PDGF D results in increased matriptase expression in the human
prostate carcinoma cell line LNCaP
While it has been shown that PDGF D can be processed by uPA into its active
form, LNCaP cells express little to no uPA but are able to process PDGF D into the
active growth domain (GD), suggesting an additional protease is able to process PDGF D
(169). Given that recombinant PDGF D is more readily processed into the active GD in
LNCaP-PDGF D cells as compared to LNCaP-neo cells, it is likely that a PDGF Dinducible protease is responsible for processing PDGF D in LNCaP cells (170).
Matriptase, a type II transmembrane serine protease, was identified by microarray to be
increased in LNCaP-PDGF D cells (Table 6). This increase in matriptase expression was
Gene Symbol
Gene Name
Fold Change
SMTN
Smoothelin
7.41
ST14
Suppression of tumorigenicity 14 (matriptase)
2.51
CCR1
Chemokine (C-C motif) receptor 1
1.74
CXCR4
Homo sapiens chemokine receptor (CXCR-4)
1.55
PRKCBP1
Protein kinase C binding protein 1
-1.55
HMMR
Hyaluronan-mediated motility receptor (RHAMM)
-1.72
RAB3GAP
RAB3 GTPase-activating protein
-1.78
CCRL2
Chemokine (C-C motif) receptor-like 2
-2.61
!"#$%& '(& )*%+,-.-/",-0+& 0.& 1234& 2& 5%670+6-8%& 9%+%6& -+& :;<"1& /%$$6& #=&
>-/50"55"=!"+"$=6-6(!$%&%!'()*&+,-!(.!$*/!0%*(1-2!3,&%'4/!
confirmed by Western blot and immunofluorescence (Fig. 3A and B). Previous results
from our lab have shown that incubation of PDGF D with increasing nanomolar
concentrations of the serine protease domain of matriptase results in processing of PDGF
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Fig. 3. Increased matriptase expression in LNCaP-PDGF D cells and its role in
PDGF D processing. A. Immunoblot analysis of matriptase in LNCaP-neo and LNCaPPDGF D cell lysates using M32 antibody. B. Immunofluorescent staining of matriptase in
LNCaP-neo and LNCaP-PDGF D cells using the anti-matriptase antibody M32 and
nuclear staining with DAPI. C. LNCaP-PDGF D cells were transfected with vector
control or HAI-1 expression plasmid. Immunoblot analysis of HAI-1 and !-actin (as a
loading control) in control and HAI-1 transfected cell lysates (top and middle panels,
respectively) as well as immunoblot analysis of PDGF D using conditioned medium
(bottom panel) are shown. D and E. LNCaP-PDGF D cells were transfected with nontargeting siRNA control (Cont. siRNA) or matriptase-targeting siRNA. Equal
concentrations of cells lysates (D) or equal volume of conditioned medium (E) were
analyzed by immunoblot analyses for matriptase and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, as a loading control) in panel D and PDGF D in panel E. F.
Serum-starved NIH3T3 cells were stimulated for 10 minutes with CM collected from nontarget siRNA control or matriptase-knockdown cells. Phosphorylated-!-PDGFR was
analyzed using anti-phosphorylated-!-PDGFR (pY751) Ab (top panel). The blot was
reprobed with anti-!-PDGFR Ab (bottom panel). G. Recombinant PDGF D (rPDGF D)
was incubated with serum-starved control or matriptase-knockdown cells for 4 hr, after
which the medium was collected from the cells. PDGF D dimer species were analyzed by
immunoblot analysis under non-reducing condition (right panel). The input rPDGF D is
shown in the left panel. FL-M, full-length PDGF D monomer; GD- M, growth factor
domain monomer; FL-D, full-length PDGF D dimer; GD-D, growth factor domain dimer.
Data courtesy of Carolyn V. Ustach.
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D into its active 18kDa growth factor domain, followed by further processing into an
inactive 15kDa form (manuscript in preparation). As determined by fellow lab member
Dr. Wei Huang, transfection of LNCaP-PDGF D cells with HAI-I, an inhibitor of
matriptase, resulted in decreased processing of PDGF D into its active growth factor
domain (Fig. 3C). Additionally, knockdown of matriptase expression with siRNA
similarly resulted in decreased processing of PDGF D (Fig. 3D and E). Consistently, the
decreased processing of PDGF D in matriptase-knockdown cells resulted in diminished
activation of !-PDGFR, as determined by Dr. Huang (Fig. 3F). These results suggest that
matriptase is able to process full length (FL) PDGF D into its growth factor domain in
vitro.
B. Expression of matriptase in murine skin results in an increase in PDGF D
expression and activation of !-PDGFR
To examine the processing of PDGF D by matriptase in vivo, we obtained skin
sections from matriptase transgenic mice through collaboration with Dr. Thomas Bugge
at NIH. In these mice, matriptase expression was driven by the keratin-5 promoter. Thus,
matriptase was overexpressed in keratin-5-expressing tissues such as the epidermis (102).
Matriptase transgenic mice exhibited interfollicular hyperplasia, epidermal dysplasia,
follicular transdifferentiation, dermal fibrosis, and inflammation. In the control mice,
weak staining of both PDGF D and phosphorylated !-PDGFR was detected in the
epidermis and sebaceous glands. However, matriptase transgenic mice exhibited
markedly increased expression of PDGF D and activated !-PDGFR in the epidermis and
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Fig. 4. PDGF D/!-PDGFR signaling axis in matriptase transgenic mice.
Sections of skin were taken from newborn mice (A), 10-12 month old mice (B),
10-12 month old skin treated with DMBA (C), or from a spontaneous tumor (D).
Sections from wild type, matriptase transgenic, HAI-1 transgenic, and
matriptase/HAI-1 double transgenic mice were immunostained with antibodies
against PDGF D or phosphorylated !-PDGFR. Images were taken at 20X
magnification.

!

""!

hair follicles. Matriptase/HAI-1 transgenic mice exhibited weak staining of both PDGF D
and phosphorylated !-PDGFR (Fig.4).

Consistently, these matriptase/HAI-I double

transgenic mice do not exhibit the premalignant changes found in the matriptase
transgenic mice (102).
List et al reported that that 100% of the matriptase mice developed epidermal
neoplasias by the age of 23 months, with 70% of these lesions being squamous cell
carcinoma. Additionally, a single treatment with DMBA induced tumors in 38/40
matriptase transgenic mice within 40 weeks after exposure, as compared to just 1/59 wild
type littermates (102). Immunohistochemistry revealed high levels of PDGF D and
activated !-PDGFR in these tumors (Fig. 4D). These results suggest a strong correlation
between matriptase expression and the PDGF D/!-PDGFR signaling axis.
C. PDGF D and matriptase are upregulated in human prostate cancer.
To examine the association of PDGF D and matriptase expression with prostate
carcinoma (PCa) stage, immunohistochemical staining for PDGF D and matriptase was
performed on both normal prostate and PCa specimens. A blind assessment of the
percentage of cells stained for PDGF D and matriptase was performed for quantitation
(Tables 7 and 8). Kendall’s tau analysis was used to assess the association between
tumor stage and Gleason score with PDGF-D and matriptase staining. As shown in Table
9, PDGF-D staining is associated with both higher tumor stage (p=0.006) and higher
Gleason score (p=0.01). Matriptase has a weaker association with both tumor (p=0.08)
and Gleason score (p=0.11). When the staining patterns of PDGF D and matriptase were
analyzed, expression of both markers in normal prostatic glands was predominantly in the
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Tumor
Stage
Normal
BPH
PIN
T2
T3a
T3b
Gleason
Score
Normal
BPH
PIN
6
7
8
9

"#!

No. of
Patients
2
2
2
29
18
13
No. of
Patients
2
2
2
13
40
6
1

0-19% tumor
cells stained
2
2
0
9
2
1
0-19% tumor
cells stained
2
2
0
5
7
0
0

20-39% tumor
cells stained
0
0
2
9
2
6
20-39% tumor
cells stained
0
0
2
1
14
2
0

40-59% tumor
cells stained
0
0
0
7
5
5
40-59% tumor
cells stained
0
0
0
4
10
3
0

60-79% tumor
cells stained
0
0
0
1
2
1
60-79% tumor
cells stained
0
0
0
1
2
1
0

80-100% tumor
cells stained
0
0
0
3
7
0
80-100% tumor
cells stained
0
0
0
2
7
0
1
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Table 7. Analysis of PDGF D staining in human PCa. Cases were grouped according to tumor
stage and Gleason score and the percent of tumor cells stained in each tissue section, as determined
blindly by a uro-pathologist.
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Table 8. Analysis of matriptase staining in human PCa. Cases were grouped according to tumor
stage and Gleason score and the percent of tumor cells stained in each tissue section, as determined
blindly by an uro-pathologist.
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A.

PDGF D

B.

Benign

HGPIN

Gleason Score 6

Gleason Score 9

Negative Control

Matriptase

Fig. 5. Expression of
PDGF D and
matriptase in human
prostate carcinoma.
Sections of benign
glands, high-grade
prostatic intraepithelial
neoplasia (HGPIN), and
tumor glands from
Gleason scores 6 and 9
were immunostained
with antibodies against
PDGF D (A) and
matriptase (B). Images
were taken at 200X
magnification. Insert
shows the enlargement of
boxed area. Basal cells
and secretory cells in the
prostate glands are
indicated by the black
arrows and red arrow
heads, respectively. In
negative control
experiments,
immunohistochemistry
was performed on human
prostate carcinoma
without the
corresponding primary
antibody.
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PDGF D

N Tumor Stage Gleason Score
66 0.27 (0.006)
0.25 (0.01)

Matriptase 62

0.18 (0.08)

A.

Benign

B.

Gleason Score 6

0.17 (0.11)

!
Table 9. Kendall’s tau analysis was
used to assess the association between
AJCC tumor stage and Gleason score
with PDGF D and matriptase staining.
p-value is shown within parentheses.

C.

Gleason Score 8

D.

Negative Control

peripheral basal cells but not in luminal
cells.

Increased expression of both

markers was also observed in some of
the glands with high-grade prostatic
intraepithelial neoplasia (HGPIN). The
neoplastic glands in well to moderately
differentiated PCa (Gleason score 6)
largely showed focal and variable

Fig. 6. Expression of PDGF D mRNA in
human prostate carcinoma. In situ
hybridization was performed on sections of
benign glands (A) and tumor glands from
Gleason scores 6 (B) and 8 (C) using PDGF
D antisense probes. Images were taken at
200X magnification. Insert shows the
enlargement of boxed area. PDGF D sense
probe was used as a negative control on
human prostate carcinoma (D).

staining. Significantly increased staining of both markers was observed in poorly
differentiated PCa (Gleason score 8 or higher) (Fig. 5). In situ hybridization of PDGF D

Fig. 7. Expression of activated !-PDGFR in benign and malignant human prostate
glands. Sections of benign, high-grade prostatic intraepithelial neoplasia (HGPIN), low
grade (Gleason score 7) and high grade (Gleason score 9) prostate carcinoma were
immunostained with an antibody against phospho-!-PDGFR. Images were taken at 200X
magnification.
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PDGF D

Matriptase

Phospho-!-PDGFR

PNI

A.

Mucinous PCa

B.

C.
PDGF D

Matriptase

Fig. 8. Expression of PDGF-D, matriptase, and phosphorylated-!-PDGFR in PNI
and mucinous prostate carcinoma and bone metastases. A, B) Serial sections of
neoplastic glands with perineural invasion (PNI, at 400X) (A) and sections of the
mucinous variant of poorly differentiated prostate cancer (mucinous PCa, at 200X) (B)
were immunostained with anti-PDGF D growth factor domain, anti-matriptase, and antiphospho-!-PDGFR antibodies. Carcinoma and nerve cells are indicated by the red arrow
heads and black arrows, respectively. C) Prostate cancer bone metastases were
immunostained with anti-PDGF D growth factor domain and anti-matriptase antibodies.
Right panels are enlargements of boxed areas in left panels.
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mRNA was also performed, in which PDGF D mRNA was found to be expressed in

epithelial cells. Consistent with the IHC, PDGF D mRNA was located in the basal cells,
but not secretory cells, of benign prostatic glands, whereas expression was increased in
poorly differentiated prostate carcinoma cells (Fig. 6). Staining for the phosphorylated
form of !-PDGFR revealed increased activation of the receptor in high grades of prostate
cancer (Fig. 7). Additionally, both PDGF D and matriptase were observed in aggressive
prostate cancer cases, such as areas of perineural invasion (PNI), a mucinous variant of
prostate cancer, and bone metastases. !-PDGFR was also found to be activated in these
cases (Fig. 8).
Immunofluorescence was also used to examine colocalization of PDGF D and
matriptase in PCa. Colocalization of PDGF D and matriptase were detected in prostate
Gleason Score 8
A. DAPI

PDGF D

Matriptase

PDGF D +
Matriptase

Mucinous Variant
B. DAPI

PDGF D

Matriptase

PDGF D +
Matriptase

Negative Control
C. DAPI

PDGF D

Matriptase

PDGF D +
Matriptase

Fig. 9. Co-localization of PDGF D and matriptase. Immunofluorescence analysis of
matriptase (Texas Red) and PDGF D (FITC-Green) in human prostate carcinoma with
Gleason score 8 (A) and in a mucinous variant of prostate carcinoma (B) was performed
at 630X magnification. Cell nuclei were stained with DAPI (blue). Yellow in the merged
panel indicates co-localization of the proteins. C) A negative control of co-localization
study was performed with indicated secondary antibody without primary antibody.
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carcinoma specimens as well as in the mucinous variant of PCa (Fig. 9).
Taken together, these results suggest that PDGF D is able to be processed by
matriptase in prostate cancer, allowing for activation of !-PDGFR signaling and cancer
progression.
3.2 Regulation of PDGF Expression by PTEN
A. PDGF Expression Changes with PTEN Expression
Given these findings of an increase in PDGF D expression in PCa, the mechanism
for this change in
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Fig. 10. Loss of PTEN modulates expression of
PDGFs/PDGFR. A) mRNA expression levels of PTEN, PDGF
ligands and receptors, matriptase, and uPA in PTEN +/+, +/-,
and -/- cells were analyzed by RT-PCR. B) CM was collected
from serum-starved PTEN +/+, +/-, and -/- cells, resolved on
reducing SDS-PAGE, and immunoblotted with anti-PDGF D
antibody. rPDGF D was used as positive control. FL-M: Full
length monomer; GD-M: Growth domain monomer.

is frequently lost or
mutated in human
prostate

cancer.
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provide
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setting PDGF D in

PCa. To this end prostate epithelial cells were obtained from Pten+/+, Pten+/-, and Pten-/-
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mice. In these mice, Cre expression was driven by the prostate specific, androgen
responsive probasin promoter. Therefore, expression of androgens after five weeks of age
results in deletion of exon 5 of Pten in the Pten+/- and Pten-/- mice. Exon 5 contains the
phosphatase domain of PTEN, thus deletion of this exon results in loss of function of
PTEN. By 8 weeks of age, all Pten-/- mice developed prostate carcinoma (14). PDGF
expression in all three cell lines was determined through RT-PCR. PDGF B was
expressed in Pten+/+ and Pten+/- cells but not Pten-/- cells. Conversely, PDGF D and !PDGFR were expressed in Pten-/- but not Pten+/+ or Pten+/- cells (Fig. 10A). To verify
protein expression, western blotting was performed. Consistent with mRNA levels,
PDGF D expression increased in Pten-/- cells as compared to Pten+/+ or Pten+/- cells (Fig.
10B). These results suggest that PTEN plays an important role in regulating the
expression of PDGF family members.
B. PDGF D and Activation of !-PDGFR Are Increased in Pten-/- Mice
To confirm that PDGF status is altered in vivo, tissue sections and lysate were
obtained

from

the

prostate

of

eight

week

old

Pten+/+

and

Pten-/-

mice.

Immunohistochemistry was performed on the tissue sections using antibodies directed
against either PDGF D or activated, phosphorylated !-PDGFR. As shown in Figure 11A,
PDGF D expression was increased in Pten-/- mice as compared to Pten+/+ mice, consistent
with what was found in the cell lines. Additionally, phosphorylated !-PDGFR levels also
increased in Pten-/- mice, suggesting that the increased levels of PDGF D were able to
activate the receptor. Western analysis of tissue lysate from Pten+/+ and Pten-/- prostate
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Fig. 11. Activation of PDGF D/!-PDGFR in prostate tumors in PTEN-/- mice. A,
B) Prostate tissue sections from PTEN+/+ and PTEN-/- mice were immunostained
with antibodies against PDGF D (A) or active, phosphorylated !-PDGFR (B). Images
were taken at 200X. VP: ventral prostate; DL: dorsolateral prostate; AP: anterior
prostate. . C, D) Prostate tissue lysate from PTEN+/+ and PTEN-/- mice were
resolved on non-reducing SDS-PAGE, followed by immunoblot analysis with antiPDGF D (C) or anti-matriptase (D) antibody. Two mice per group were analyzed, as
designated by numbers 1-4. FL-D: Full length dimer; GD-D: Growth domain dimer.
*: 70kD Matriptase with 55kD HAI-I; **: 70kD Matriptase with serine protease
domain of HAI-I
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also revealed increased levels of PDGF D. Importantly, PDGF D was found in both the
inactive, full-length form as well as the activated, growth domain form (Fig. 11B).
Additionally, Pten-/- mice exhibited increased levels of matriptase (data courtesy of Dr.
Wei Huang) (Fig. 11C). These results suggest that loss of PTEN is also associated with
PDGF expression in vivo.
C. PDGF Expression Is Regulated through the PI3K/Akt Pathway
PTEN is known to regulate many signaling pathways, including PI3K and MAPK
pathways. Therefore, inhibitors of PI3K, MEK, JNK, and mTOR were used to identify
the signaling pathway that regulates PDGF expression downstream of PTEN. LY294002
and wortmannin inhibit PI3K activity through two distinct mechanisms. Inhibition of
PI3K by LY294002 arises from its competitive inhibition of the ATP binding site on the
p85! subunit, whereas wortmannin exhibits an irreversible, covalent interaction with the
p110 subunit (134, 176, 183). PD98059 inhibits the MAPK pathway by binding to MEK
(MAPK kinase), preventing its activation by Raf-1; this inhibition of MEK results in an
inhibition of ERK1/2 activation (2). JNK Inhibitor II binds to the ATP binding site of
JNK (12, 148). mTOR is inhibited by rapamycin through its binding of mTOR in
complex with FK506-binding protein (FKBP12), thus blocking binding of the lipid
second messenger phosphatidic acid (PA) to mTOR (24, 40).
Treatment of Pten-/- cells with MEK, JNK, and mTOR inhibitors did not alter
PDGF mRNA expression (Fig. 12A-C). However, inhibition of PI3K with either
LY294002 or wortmannin resulted in decreased expression of both PDGF D and !PDGFR (Fig. 12D and E). These results suggest that PDGF/PDGFR mRNA expression is
regulated through the PI3K pathway.
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Fig. 12. The PTEN/PI3K pathway regulates PDGF expression. PTEN -/- cells
were treated for 2 days with Rapamycin (mTOR inhibitor) (A), or overnight with
increasing concentrations of JNK Inhibitor II (B), PD98049 (C), LY294002 (D), and
wortmannin (E), inhibitors of JNK, MAPK, and PI3K, respectively. mRNA
expression levels were analyzed by RT-PCR.

D. Akt3 Expression Increases with Loss of Pten
Given that Akt is a downstream effector of PI3K, the expression of the three Akt
isoforms were next analyzed. RT-PCR revealed that Akt1 mRNA levels are consistent
throughout the three cell lines, whereas Akt3 is increased in Pten-/- cells as compared to
Pten+/+ and Pten+/- cells (Fig. 13A). Similar results were found with protein levels of the
three isoforms (Fig. 13B). Furthermore, inhibition of Akt, downstream of PI3K, also
reduced expression of PDGF D and !-PDGFR in Pten-/- cells (Fig. 13C). These results
suggest that Akt3 is responsible for changes in PDGF expression in the Pten-/- cell line.
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Fig. 13. Loss of PTEN leads to increased Akt3 expression. Expression of Akt
isoforms in PTEN +/+, +/-, and -/- cells were determined by RT-PCR (A) and western
blotting (B). C) . PTEN -/- cells were treated overnight with increasing concentrations of
Akt Inhibitor IV. mRNA expression levels were analyzed by real time RT-PCR.

E. In vitro Loss of Pten Results in Changes in PDGF Expression
To further confirm the role of PTEN in PDGF expression, the wild type
PtenloxP/loxP cell line was infected with Cre through the use of a lentivirus, thus allowing
for loss of PTEN in vitro. Similar to what is observed upon PTEN loss in vivo, cells in
which PTEN expression was lost in vitro exhibit decreased expression of PDGF B and
increased expression of PDGF D, relative to wild type PtenloxP/loxP cells (Fig. 14A).
Expression of the Akt isoforms was also examined by western blot; Akt1 protein
expression was similar amongst all cell lines, whereas Akt2 and Akt3 expression was
increased in the pooled population of the in vitro PTEN knockout cells (Fig. 14B).
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Fig. 14. In vitro loss of PTEN regulates PDGF expression through PI3K/Akt
pathway. A) mRNA expression levels of PTEN, !-PDGFR and its ligands, PDGF B
and PDGF D, in PTEN wild type (LoxP/LoxP) and knockout cells were analyzed by
RT-PCR. B) Expression of Akt isoforms in PTEN wild type and knockout cells were
determined by western blotting. C) PTEN knockout cells (clone 2) were treated
overnight with increasing concentrations of LY294002 (upper panel) or Akt Inhibitor
IV (lower panel). mRNA expression levels were analyzed by real time RT-PCR. PP:
PTEN knockout pooled population; #2: PTEN knockout clone 2; #3: PTEN knockout
clone 3; #4: PTEN knockout clone 4
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Fig. 15. The PTEN/PI3K pathway modulates PDGF/PDGFR expression in
human PCa. A) mRNA expression levels of PTEN, PDGF ligands, and Akts
were analyzed by RT-PCR in human PCa cell lines DU145 and PC3. B)
DU145 and PC3 lysate was collected and resolved on non reducing SDSPAGE, and immunoblotted with antibodies directed against Akt isoforms and
phosphorylated Akt. C,D) PC3 cells were treated overnight with increasing
concentrations of LY294002 (C) or Akt Inhibitor IV (D). mRNA expression
levels were analyzed by real time RT-PCR.
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Additionally, when PTENL/L CreIIa cells were treated with inhibitors of PI3K or Akt,
expression of PDGF D decreased (Fig. 14C).
F. Inverse Association between PTEN Status and PDGF Expression in Human
Prostate Cancer
To investigate the role of PTEN in PDGF expression in human prostate cancer,
the cell lines DU145 and PC3 were analyzed for PDGF expression. As shown previously,

Growth Factor
Growth Factor
Receptor

Matriptase,
uPA
Pro-PDGF D
PDGF D

!-PDGFR
!-PDGFR

!-PDGFR
!-PDGFR

Tumor Cell

Stromal
Cell
Fig. 16. Working model of Matriptase/PDGF D/!-PDGFR signaling axis in
human prostate carcinoma. Loss of PTEN, a common occurrence in PCa, results in
increased expression of PDGF D and !-PDGFR. PDGF D is then able to be processed
by matriptase/uPA, allowing for autocrine and paracrine signaling through activation
of !-PDGFR on both tumor and stromal cells.
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DU145 expresses wild type PTEN, whereas PC3 does not express PTEN (177).
Additionally, DU145 and PC3 express similar levels of both Akt1 and Ak2 mRNA and
protein, whereas expression of Akt3 mRNA is increased in PC3 cells (Fig. 15A-B).
Similar to the PTEN-/- murine cells, PC3 exhibits decreased levels of PDGF B mRNA
and increased levels of PDGF D mRNA, relative to DU145. Furthermore, inhibition of
either PI3K or Akt resulted in decreased levels of PDGF D mRNA in PC3 cells (Fig.
15C). Taken together, these results suggest that the PTEN/PI3K/Akt pathway regulate the
PDGF D/!-PDGFR signaling axis in human prostate carcinoma (Fig. 16).
!
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Chapter 4
Discussion
Previous studies have shown that !-PDGFR expression is upregulated in human

prostate carcinoma, while its classical ligand PDGF B is not detected. !-PDGFR has also
been indicated to be one of five key genes, along with chromogranin A, HOXC6, IPTR3,
and sialyltransferase-1, that are able to predict prostate cancer recurrence (150). PDGF B
was originally thought to be the sole ligand for !-PDGFR; thus, the lack of detection of
PDGF B in prostate cancer lead to the question of a clinically relevant ligand for !PDGFR in human prostate cancer. Through the use of immunohistochemistry and in situ
hybridization, the results shown in this dissertation reveal for the first time that PDGF D
expression is increased in human prostate carcinoma (Figs. 5-6). Thus, the novel finding
of an association of PDGF D with increasing prostate cancer tumor stage and Gleason
score indicates for the first time the PDGF ligand that is able to activate !-PDGFR in
prostate cancer.
Previous work in our lab has established that the serine protease matriptase is
capable of processing PDGF D into its active growth factor domain form in vitro. In an
effort to establish the ability of matriptase to process PDGF D in vivo,
immunohistochemistry and immunofluorescence studies were performed with human
prostate cancer samples, as well as in a murine model. In the matriptase transgenic mouse
model, in which matriptase is upregulated in keratinocytes, increased expression of
matriptase resulted in increased activation of !-PDGFR in the skin of these mice (Fig. 4).
Matriptase expression is also associated with human prostate cancer tumor stage and
Gleason score, in a manner similar to PDGF D (Fig. 5). Importantly, PDGF D and
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matriptase colocalize in human prostate cancer (Fig. 9). These results support the
hypothesis that matriptase can cleave the CUB domain from PDGF D, resulting in an
active growth factor.
Taken together with previous findings, the results of this dissertation show that
PDGF B and PDGF D exhibit different expression patterns in prostate cancer.
Importantly, our findings that PDGF D and PDGF B have distinct expression signatures
is not unique to the prostate, as determined by previous studies. PDGF D is expressed at
high levels in the adrenal gland, pancreas, and testis, where little to no PDGF B is
detected by real time PCR (82). Additionally, Bergsten et al has reported that PDGF D
and PDGF B are expressed in distinct cellular components of the embryonic kidney (13).
Immunohistochemistry revealed that PDGF D is expressed in the fibrous capsule of the
kidney, the metanephric mesenchyme of the cortex, and the basal aspect of the branching
ureter. !-PDGFR is also expressed in the metanephric mesenchyme as well as vascular
smooth muscle cells (7, 96). PDGF B, however, is expressed only in the endothelial cells
(96). These expression patterns suggest that PDGF B and PDGF D play separate roles in
the developing kidney, with PDGF D playing a role in the proliferation of the
metanephric mesenchyme that express !-PDGFR and PDGF B suggested to be important
in the vascularization of the kidney. Given the frequent expression of one, but not both,
ligands for !-PDGFR, it is likely that PDGF B and PDGF D may serve distinct functions
in specific tissues. For example, it has been suggested that it is possible that the distinct
expression of PDGF D but not PDGF B in certain tissues is due to the ability of PDGF D
to stimulate cells that express either !-PDGFR or both "- and !-PDGFR without
stimulating nearby cells that express only "-PDGFR.
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Interestingly, PDGF D expression in benign prostatic glands was seen exclusively

in the basal cells but not secretory cells, whereas PDGF D expression in neoplastic glands
was seen in luminal cells (Fig. 5). Current research indicates the possibility that prostate
cancer arises from the transformation of basal cells to neoplastic secretory cells (3, 106).
Thus, it is possible that PDGF D plays a role in the neoplastic transformation of these
cells. Additionally, PDGF D and matriptase expression was detected in areas of
neoplastic glands surrounding nerves, known as perineural invasion (PNI) (Fig. 8).
Although controversial, PNI has been shown to be associated with increased tumor size,
risk of recurrence, and metastasis (11, 84, 175).
In an effort to determine the mechanism resulting in the increased expression of
PDGF D and !-PDGFR in prostate cancer, we turned to the PTEN model due to the fact
that PTEN is a critical regulator of growth factor signaling and is frequently lost or
mutated in prostate cancer. To this end, the murine model in which PTEN expression is
lost specifically in the prostate is a useful model for studying the regulation of PDGF
expression. Given that complete loss of PTEN expression is embryonically lethal, the
prostate-specific model used for these studies provides a valuable tool for studies of the
role of this important gene in prostate cancer formation and progression. Upon loss of
PTEN in vivo, PDGF D expression and activation of !-PDGFR increases, as determined
through immunohistochemistry as well as western blotting (Fig. 11). In cells derived
from these prostate specific Pten-/- mice, loss of PTEN also resulted in decreased PDGF B
mRNA expression with a concomitant increase in PDGF D and !-PDGFR mRNA
expression (Fig. 10). Through the use of inhibitors of signaling pathways regulated by
PTEN, it was determined that PDGF D/!-PDGFR expression was regulated through the
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PI3K/Akt pathway (Figs. 12-13). The role of the PI3K/Akt signaling pathway in the
expression of PDGF D and !-PDGFR was also established in human prostate cancer
cells. The human prostate cancer cell line PC3, which lacks PTEN expression, exhibits
increased expression of PDGF D relative to DU145, which expresses a functional PTEN
(Fig. 15). Additionally, inhibition of either PI3K or Akt in PC3 cells results in decreased
expression of PDGF D, showing that the PI3K/Akt pathway is necessary to maintain
PDGF D expression.
In both murine and human prostate cancer cells lacking PTEN, there is an
increase in the expression of Akt3 at both the mRNA and protein level, suggesting that
this Akt isoform may be responsible for controlling PDGF D and !-PDGFR expression
(Figs. 13 and 15). Unfortunately, experiments in which each Akt isoform was knocked
down through the use of siRNA proved to be inconclusive, as the decreased expression of
one Akt isoform lead to the increase of expression of the two remaining Akt isoforms
(data not shown). In these experiments, PDGF D and !-PDGFR expression was not
significantly altered upon loss of any one Akt isoform, possibly due to compensatory
features of the different isoforms. Thus, this study was unable to conclusively prove
whether one specific Akt isoform is responsible for regulation of PDGF D or !-PDGFR
expression, or if all three isoforms are capable of this regulation of expression.
Our lab has previously found that conditioned media from LNCaP cells
transfected with PDGF D enhance fibroblast motility. Additionally, LNCaP-PDGF D
cells exhibit accelerated onset of prostate tumor growth in a subcutaneous injection SCID
mouse model; two weeks post-injection, one out of five mice injected with LNCaP-neo
developed tumors, whereas five out of five mice injected with LNCaP-PDGF D
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developed tumors. Additionally, in this subcutaneous injection model, LNCaP-neo cells
generated well-encapsulated tumors, whereas LNCaP-PDGF D tumors displayed a
drastically enhanced invasion!$%&'!&()!*+,,'+%-$%.!*&,'/01!2()*)!,)*+3&*!-)/'%*&,0&)!
0!4'&)%&$03!'%5'.)%$5!05&$6$&7!'8!9:;<!:!$%!&()!-)6)3'4/)%&!0%-=',!4,'.,)**$'%!'8!
4,'*&0&)!50%5),!>?@AB1!;$6)%!&()*)!4,)6$'+*!8$%-$%.*C!&0D)%!&'.)&(),!E$&(!&()!,)*+3&*!
*('E%! (),)C! $&! $*! 3$D)37! &(0&! $%5,)0*)-! 3)6)3*! '8! 9:;<! :! $%! 4,'*&0&)! 50,5$%'/0! 50%!
*&$/+30&)!&()!.,'E&(!'8!&()!&+/',1!!
Furthermore, unpublished data from our lab strongly supports the oncogenic
effects of PDGF D. Preliminary data from our lab has shown that normal murine prostate
epithelial cells transfected with PDGF D display increased migration and invasion, as
compared to both control cells and cells transfected with PDGF B. These PDGF D
transfected cells also expressed increased levels of phosphorylated ERK and JNK
(unpublished data, courtesy of Dr. Abdo Najy). Expression of PDGF D was also able to
induce osteoblastic differentiation in MC3TS cells through stimulation of !-PDGFR and
Akt, as determined by staining for mineralization as well as RT-PCR for the osteoblast
differentiation marker osteocalcin and transcription factor Runx2. Importantly, in an
intratibial injection model, LNCaP-PDGF D cells exhibit increased tumor take and
growth rate as compared to control LNCaP-neo cells. In mice with these LNCaP-PDGF
D tumors, there is also an increased mixed osteolytic/osteoblastic response, as determined
by TRAP staining, indicating osteolytic responses, as well as trichrome staining,
indicating osteoblastic responses. Conversely, LNCaP-neo derived tumors exhibited a
solely osteoblastic response (manuscript in preparation). Additionally, as discovered by
Dr. Wei Huang, PDGF D is able to induce osteoclastogenesis in a RANK/RANKL
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Fig. 17. Potential methods for PDGF D induction of osteoclastogenesis.
independent manner. Using RAW264.7 cells, Dr. Huang determined that treatment of
pre-osteoclasts with rPDGF D induced osteoclast differentiation as determined by tartrate
resistant acid phosphatase (TRAP) staining. rPDGF D treatment also resulted in increased
expression of $%&'()*!+)&,-*!-+!)&,./),(0!1!&(''2!3!(NFATc1), a key transcription factor
in osteoclastogenesis. Interestingly, PDGF B was unable to induce these osteoclastic
effects, suggesting that PDGF D exhibits distinct functions in osteoclastogenesis from
that of PDGF B. To this end, we raise four hypotheses as to the mechanism for the unique
PDGF D signaling capabilities, as depicted in Fig. 17. First, activation of a unique
receptor by the CUB domain subsequent to its proteolytic removal may result in
osteoclastogenic signaling in cooperation with !-PDGFR signaling that is induced by the
PDGF D growth factor domain (Fig. 17, Hypothesis 1). Our second hypothesis involves
the PDGF D hemidimer, which is produced by the removal of one CUB domain, creating
a dimer consisting of one full length PDGF D monomer and one growth factor domain
monomer, as depicted in Fig. 2. In this hypothesis, binding of the growth factor domain
subunit of the hemidimer to one !-PDGFR subunit could result in the recruitment by the
CUB domain of additional cell surface signaling molecules. Subsequent to further
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processing of the hemidimer into the growth factor domain dimer, !-PDGFR could then
activate unique signaling pathways to initiate osteoclastogenesis (Fig. 17, Hypothesis 2).
The third hypothesis is that the CUB domain of the hemidimer results in
heterodimerization of !-PDGFR with an unknown receptor, inducing signaling pathways
leading to osteoclastogenesis (Fig. 17, Hypothesis 3). The exact mechanism of the
induction of osteoclastogenesis is an exciting area of study that is under investigation in
our lab.
Importantly, human prostate cancer bone metastasis is characterized by both
osteolytic and osteoblastic responses (115). Thus, PDGF D expression induces a bone
response typical of human prostate carcinoma. #$%! &'()*! +,-%! .)*! /*)+-'-%! 0'10%*!
&%-'+-'+,+! ,+! -$%! 2)1%3! 4&/)*-'1-567! 2)-$! &'-*,/-'+%! '18! 9:;<! :! %=/*%++,)1! >%*%!
8%-%0-%8! ,1! 2)1%! &%-'+-'-,0! +'&/5%+! ).! $?&'1! /*)+-'-%! 0'*0,1)&'! @<,A3! BC3! #$?+7!
-'*A%-,1A! -$%! &'-*,/-'+%D9:;<! :D!E9:;<F! +,A1'5,1A! '=,+! 0)?58! /*)G,8%! '! +/%0,.,0!
-$%*'/%?-,0! '//*)'0$! .)*! /*)+-'-%! 0'10%*3! H$,5%! /'-,%1-+! >,-$! /*,&'*6! /*)+-'-%!
0'10%*!$'G%!+%G%*'5!-*%'-&%1-!)/-,)1+7!+?0$!'+!+?*A%*67!*'8,'-,)17!$)*&)1%!-$%*'/67!
)*! %G%1! I>'-0$.?5! >',-,1A7J! -$%*'/6! 0$),0%+! .)*! &%-'+-'-,0! /*)+-'-%! 0'10%*! ,+! &)*%!
5,&,-%8!'187!?1.)*-?1'-%567!5%++!%..%0-,G%3!
!E9:;<F! $'+! 2%%1! .)?18! -)! ?/*%A?5'-%8! ,1! BKL! ).! 2)-$! /*,&'*6! /*)+-'-%!
0'10%*!'+!>%55!'+!2)1%!&%-'+-'+%+!@MNC3!O88,-,)1'5567!!E9:;<F!,+!,8%1-,.,%8!'+!/'*-!).!
'!.,G%EA%1%!&)8%5!-$'-!/*%8,0-+!/*)+-'-%!0'10%*!*%0?**%10%!@P"KC3!#$%*%.)*%7!9:;<F!
+,A1'5,1A! ,+! '! /)-%1-,'556! ,&/)*-'1-! -'*A%-! .)*! /*)+-'-%! 0'10%*! -$%*'/63! 41! '! &)?+%!
&)8%5!).!/*)+-'-%!0'10%*7!-*%'-&%1-!>,-$!-$%!Bcr-Abl/PDGFR/c-Kit inhibitor Gleevec
(STI571, imatinib mesylate) was shown to reduce tumor incidence and growth, and an
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increase in apoptosis in the tumor cells as well as tumor associated endothelial cells
(167). However, clinical trials with Gleevec were halted due to excessive side effects,
such as diarrhea related to inhibition of c-kit in the intestines and cardiotoxicity
associated with inhibition of c-abl in cardiac myocytes (31, 52, 72). Therefore, more
specific therapies that target PDGFR signaling could be critical for developing effective
targeted treatments. To this end, targeting PDGF D could result in more effective PDGFR
related therapies with less toxicity, through targeting either PDGF D expression through
the PTEN/PI3K/Akt pathway, or through targeting PDGF D activation by matriptase. !
As shown above, the PI3K/Akt pathway regulates PDGF D expression. It has
been previously shown that PDGF D expression is increased by luteinizing hormone
(LH) (64). In human granulose-luteal cells, treatment with LH resulted in a 4.21-fold
increase in PDGF D. Conversely, LH treatment resulted in a 41% decrease of PDGF B.
Given that LH is capable of signaling through Akt, it is possible that its effects on PDGF
D expression are through the PI3K/Akt pathway (21, 45). Additionally, it has previously
been shown by microarray that loss of Pten in murine prostate epithelial cells resulted in
a 1.42 and 1.65 increase in PDGF D and !-PDGFR, respectively (179). Thus, the results
of our study confirm the role of PTEN in PDGF D and !-PDGFR expression. Previously,
it has been shown that the PDGF D promoter contains sites regulated by the transcription
factors Ets-1 and Sp1 (104). Interestingly, both PTEN and Sp1 have been linked to
regulation of IGF-IR and VEGF (132, 192, 193). Sp1 induction of VEGF expression is
brought about by Akt activation; Pore et al determined that Akt activation lead to
increased phosphorylation of Sp1 as well as increased binding of Sp1 to the VEGF
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promoter (132). Given the degree of similarity between PDGF and VEGF family
members, regulation of PDGF D expression may be similar to that of VEGF.
In conclusion, the results discussed above, taken together with previous studies,
indicate that the matriptase/PDGF D/!-PDGFR signaling pathway may be a key factor in
prostate carcinoma. By elucidating the mechanism by which PDGF D expression is
increased by the PTEN/PI3K/Akt pathway, future therapies for prostate cancer may be
developed.
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